Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Breast Cancer Metastasis Linked to the Structural Protein Palladin

By LabMedica International staff writers
Posted on 24 Nov 2008
Cancer researchers have found that the ability of breast cancer cells to metastasize is linked to the overexpression of a membrane structural protein called palladin.
Investigators at the University of North Carolina (Chapel Hill, USA) have been studying the role of palladin in the growth and spread of cancer cells since its discovery about eight years ago.

In the current paper published in the November 3, 2008, online edition of the journal Oncogene, the investigators reported on the outcome of experiments where normal cells, non-invasive cancer cells, and invasive cancer cells were tested in special growth chambers that required the cells to degrade and migrate through a filter coated with a layer of artificial connective tissue. More...
They found that the ability to migrate through the tissue membrane depended on the cell's level of palladin expression. Palladin was expressed at higher overall levels in tumors compared with benign breast tissue, and was expressed significantly higher in four invasive breast cancer cell lines than in the non-invasive cells lines. Additionally, they found that palladin played a key role in the formation of podosomes, actin-rich structures that function in adhesion and matrix degradation, and have been found in many invasive cell types.

Cells that had been genetically engineered to lack the gene for palladin demonstrated decreased podosome formation and a significant reduction in migration and invasive motility. Palladin overexpression induced podosome formation in non-invasive MCF7 cells, which were otherwise unable to form podosomes, suggesting that palladin played a critical role in the assembly of podosomes.

"This study shows that palladin may play an important role in the metastasis of breast cancer cells as they move out of the tumor and into the blood vessels and lymphatics to spread throughout the body,” said senior author Dr. Carol Otey, associate professor of cell and molecular physiology at the University of North Carolina. "To really make breast cancer a treatable disease, we have to be able to find a way to prevent or reduce the amount of metastasis. Now that we see palladin is expressed mostly in invasive cells, it raises the question as to whether it might be useful as a prognostic marker. Maybe someday doctors could test for the presence of palladin to identify patients who have the most aggressive tumors, then give those patients personalized, more aggressive treatment.”

Related Links:
University of North Carolina


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.